Cargando…

Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance

BACKGROUND/AIMS: Real-world data about the treatment outcomes of patients receiving rituximab-containing immunochemotherapy followed by rituximab maintenance are required to understand better the treatment for follicular lymphoma (FL). METHODS: A cross-sectional study analyzed FL patients who were t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hee Kyung, Kang, Wonseok, Sinn, Dong Hyun, Lee, Joon Hyeok, Kim, Won Seog, Kim, Seok Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960034/ https://www.ncbi.nlm.nih.gov/pubmed/30935195 http://dx.doi.org/10.3904/kjim.2018.196

Ejemplares similares

Maintenance rituximab in Veterans with follicular lymphoma
por: Halwani, Ahmad S., et al.
Publicado: (2020)

Human herpesvirus-6 pneumonitis in a patient with follicular lymphoma following immunochemotherapy with rituximab
por: Kuwahara-Ota, Saeko, et al.
Publicado: (2018)

Pretreatment CT Texture Parameters as Predictive Biomarkers of Progression-Free Survival in Follicular Lymphoma Treated with Immunochemotherapy and Rituximab Maintenance
por: Durot, Carole, et al.
Publicado: (2023)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2021)

Rituximab maintenance therapy of follicular lymphoma in clinical practice
por: Dührsen, Ulrich, et al.
Publicado: (2018)

Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
por: Buchegger, Franz, et al.
Publicado: (2011)

Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma
por: Aguiar-Bujanda, David, et al.
Publicado: (2015)

Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
por: Herold, Michael, et al.
Publicado: (2022)

Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
por: Peñalver, Francisco‐Javier, et al.
Publicado: (2019)

Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma
Publicado: (2023)

Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma
por: Li, Ru, et al.
Publicado: (2022)

Correction Notice: Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
Publicado: (2022)

Cerebellum/liver index in pretherapeutic (18)F-FDG PET/CT as a predictive marker of progression-free survival in follicular lymphoma treated by immunochemotherapy and rituximab maintenance
por: Godard, François, et al.
Publicado: (2022)

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2022)

Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real‐world analysis from Taiwan Cancer Registry Database
por: Huang, Huai‐Hsuan, et al.
Publicado: (2018)

Rituximab maintenance in relapsed or refractory follicular non-Hodgkin’s lymphoma: the evidence of its therapeutic value
por: Ardeshna, Kirit M.
Publicado: (2007)

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
por: Zinzani, Pier Luigi, et al.
Publicado: (2012)

The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States
por: Nastoupil, Loretta J, et al.
Publicado: (2014)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020)

Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma: A NICE Single Technology Appraisal
por: Greenhalgh, Janette, et al.
Publicado: (2013)

A Case of Fulminant Hepatitis due to Echovirus 9 in a Patient on Maintenance Rituximab Therapy for Follicular Lymphoma
por: Morgan, Ceri, et al.
Publicado: (2015)

Rituximab pharmacokinetics in ascites and serum in the treatment of follicular lymphoma with massive ascites
por: Hiroshima, Yuki, et al.
Publicado: (2012)

Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape
por: Subramanian, Janakiraman, et al.
Publicado: (2017)

The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma
por: Fowler, Nathan H., et al.
Publicado: (2020)

Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study
por: Oh, Sung Yong, et al.
Publicado: (2019)

Too much and not enough: revisiting maintenance rituximab in indolent lymphomas
por: Smith, Sonali M.
Publicado: (2021)

Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group
por: Hirt, Carsten, et al.
Publicado: (2021)

Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study
por: Kim, Yu Ri, et al.
Publicado: (2023)

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
por: Bachy, Emmanuel, et al.
Publicado: (2019)

PB2070: EFFICACY OF RITUXIMAB MAINTENANCE THERAPY IN ADVANCED-STAGE FOLLICULAR LYMPHOMA: A SINGLE-CENTER RETROSPECTIVE STUDY.
por: Amorós, C., et al.
Publicado: (2022)

Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator
por: Kwon, Hyeok Chan, et al.
Publicado: (2020)

Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis
por: Di, Mengyang, et al.
Publicado: (2023)

Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma
por: Matasar, Matthew J., et al.
Publicado: (2021)

Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma
por: Hornberger, John, et al.
Publicado: (2008)

Follicular B Cell Lymphoma with Accompanying Ischemic Gastritis Completely Resolved by Rituximab
por: Tariq, Anam, et al.
Publicado: (2017)

Follicular Lymphomas of Oral Region Treated by Rituximab Monotherapy: About Two Cases
por: Montaner, Sylvain, et al.
Publicado: (2018)

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
por: Spencer, Scott J, et al.
Publicado: (2021)

Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
por: Yelvington, Bradley J.
Publicado: (2018)

Rituximab response in follicular lymphoma: contributions from KIR 2DS1 and HLA-C
por: Erbe, A K, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_93ihn4g38bpfa77h2tpjnqc4g8